clinic trial endpoint approv cancer drug biolog guidanc industri us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber decemb 2018 clinicalmed clinic trial endpoint approv cancer drug biolog guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 855 5433784 301 7963400 fax 301 4316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm andor offic commun outreach develop center biolog evalu research food drug administr 10903 new hampshir ave bldg 71 room 3128 silver spring md 20993 0002 phone 8008354709 240 4028010 email ocodfdahhsgov httpswwwfdagovbiologicsbloodvaccinesguidancecomplianceregulatoryinformationguidancesdefaulthtm u depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber decemb 2018 clinicalmed contain nonbind recommend tabl content introduct 1 ii background 2 statutori regulatori requir effect 2 b endpoint support past approv oncolog 3 iii gener endpoint consider 4 overal surviv 7 b endpoint base tumor assess 7 1 diseas free surviv event free surviv 8 2 object respons rate 9 3 complet respons 9 4 time progress progress free surviv 10 5 time treatment failur 11 c endpoint involv symptom assess 11 1 specif symptom endpoint 11 2 problem encount symptom data 12 blood bodi fluid base biomark 12 e emerg endpoint 12 iv clinic trial design analysi consider 13 singl arm studi 13 b random studi design demonstr noninferior 13 c trial design radiotherapi protect chemotherapi protect 14 clinic trial design consider 14 e clinic trial analysi issu 14 v conclus 15 appendix independ review tumor en dpoint 16 contain nonbind recommend 1 clinic trial endpoint approv cancer drug biolog guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right pe rson bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons guidanc li ted titl page introduct guidanc provid recommend applic endpoint cancer clinic trial submit food drug administr fda support effect claim new drug applic nda biolog licens applic bla supplement applications2 also provid background inform discuss gener regulatori principl endpoint discuss guidanc drug treat patient exist cancer3 guidanc address endpoint drug prevent decreas incid cancer guidanc revis final guidanc titl publish may 2007 guidanc replac may 2007 guidanc titl gener fda guidanc document establish legal enforc respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori requir cite use word agenc guidanc mean someth suggest recommend requir 1 guidanc prepar oncolog center excel center drug evalu research cder center biolog evalu research cber food drug administr 2 purpos guidanc refer drug includ human drug biolog product unless otherwis specifi 3 see guidanc industri clinic trial endpoint approv non small cell lung cancer drug biolog recommend specif non small cell lung cancer clinic trial see guidanc industri patholog complet respons neoadjuv treatment high risk earli stage breast cancer use endpoint support acceler approv recommend specif high risk earli stage breast cancer updat guidanc period make sure recent versio n guidanc check fda w eb page guidanc mention document avail bio logic guidanc w eb page httpwwwfdagovbiologicsbloodvaccinesguidancecomplianceregulatoryinformationguidancesdefaulthtm andor drug guidanc web p age httpwwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm contain nonbind recommend 2 ii background clinic trial endpoint serv differ purpos convent oncolog drug develop earli phase clinic trial evalu safeti identifi evid biolog drug activ tumor shrinkag endpoint later phase efficaci studi commonli evalu whether drug provid clinic benefit prolong surviv improv symptom follow section discuss gener regulatori requir efficaci influenc endpoint select approv cancer drug later section describ endpoint detail discuss whether might serv measur diseas activ clinic benefit variou clinic set statutori regul requir effect requir new drug show effect base 1962 amend feder food drug cosmet act fdc act law requir substanti evid effect specifi eviden ce must deriv adequ well control clinic investig similarli public health servic act requir biolog product safe pure potent4 clinic benefit support drug approv includ import clinic outcom eg increas surviv symptomat improv also includ effect surrog endpoint known predict clinic benefit eg blood pressur acceler approv regul 21 cfr part 314 subpart h 21 cfr part 601 subpart e promulg 1992 allow use addit endpoint approv drug biolog product intend treat seriou life threaten diseas gener demonstr improv avail ther api provid therapi none exist set fda may grant approv base effect surrog endpoint reason like predict clinic benefit5 surrog endpoint less well establish surrog endpoint tradit approv blood pressur cardiovascular diseas fda may also grant acceler approv base effect clinic endpoint measur earlier irrevers morbid mortal reason like predict effect irrevers morbid mortal clinic benefit ie intermedi clinic endpoint6 drug approv acceler approv regul condit manufactur conduct clinic studi verifi describ actual clinic benefit7 postmarket studi fail demonstr clinic benefit applic demonstr due dilig conduct requir studi among reason fda ay withdraw approv drug indication8 follow discuss term tradit approv denot longstand rout drug approv base demonstr clinic benefit effect surrog endpoint 4 potenc long interpret includ effect 21 cfr 6003 5 section 506c1b fdc act 21 cfr 314510 60141 provid agenc may consid epidemiolog therapeut pathophysiolog evid determin whether endpoint reason like predict clinic benefit food drug administr safeti innov act 2012 provid fda may consid epidemiolog pathophysiolog therapeut pharmacolog evid develop use biomark exampl scientif method tool see guidanc industri expedit program seriou condit drug biolog 6 see guidanc industri expedit program seriou condit drug biolog 7 comprehens discuss condit acceler approv discuss condit approv see guidanc industri expedit program seriou condit drug biolog 8 see section 506c3 fdc act 314530a 60143a contain nonbind recommend 3 known predic clinic benefit term distinguish acceler approv associ use surrog endpoint intermedi clinic endpoint reason like predict clinic benefit support drug approv evid need establish effect discuss guidanc industri provid clinic evid effect human drug biolog product guidanc industri fda approv new cancer treatment use market drug biolog product mani case least two adequ well control clinic investig need certain case evid singl adequ well control clinic investig confirmatori evid suffici eg case singl multicent studi provid highli reliabl statist strong evid import clinic benefit fda may consid data one adequ well control clinic investig con firmatori evid substanti evid fda determin data evid suffici establish effectiveness9 exampl drug approv treatment patient specif stage particular malign evid one adequ well control clinic investig confirmatori evid may suffici support efficaci supplement treatment differ stage cancer b endpoint support past approv oncolog tradit approv applic show direct evid clinic benefit improv surrog endpoint known predict clinic benefit oncolog surviv improv consid appropri measur clinic benefit addit ponsor use endpoint cancer drug approv 1970 fda usual approv cancer drug base object respons rate orr determin tumor assess radiolog test physic examin earli 1980 discuss oncolog drug advisori committe odac fda determin cancer drug approv base direct evid clinic benefit improv surviv improv patient qualiti life impr ove physic function improv tumor relat symptom benefit may alway predict correl orr time larger improv tumor reduct delay tumor growth seen tumor measur endpoint use support tradit acceler approv improv diseas free surviv df support drug approv select adjuv set larg proport patient expect cancer symptom time recurr durabl complet respons support tradit approv leukemia complet respons cr associ less infect bleed blood product support larg improv progress free surviv pf high substanti durabl orr use support tradit approv select malign magnitud effect relief tumor relat symptom drug toxic also consid make approv decision101112 exampl random trial 9 see section 505d amend food rug administr modern act 1997 10 blumenth gm pg klu etz j schneider kb goldberg ae mckee r pazdur 2017 oncolog drug approv evalu endpoint evid era breakthrough therapi oncologist 227 762 767 11 blumenth gm r pazdur 2016 respons rate approv endpoint oncolog back futur jama oncol 26 720 721 12 oshaughnessi witt et al1991 commentari concern demonstr safeti efficaci investig anticanc agent clinic trial j clin oncol 92225 2232 contain nonbind recommend 4 hormon drug breast cancer singl arm trial drug ros1 posit metastat nonsmal cell lung cancer use orr endpoint support traditiona l approv improv tumor relat symptom conjunct improv orr adequ respons durat support tradit approv sever clinic set surrog endpoint acceler approv must reason like predict clinic benefit fdc act 506c1a 21 cfr part 314 subpart h 21 cfr part 601 subpart e durabl orr use tradit approv endpoint circumst orr also commonli use surrog e ndpoint support acceler approv tumor respons wide accept oncologist guid cancer treatment orr directli attribut drug effect singl arm trial conduct patient refractori tumor availa ble therapi exist provid accur assess orr whether tumor measur orr pf use acceler approv tradit approv endpoint depend diseas context magnitud effect among factor see section iiib2 4 iii gener endpoint consider section provid overview gener issu cancer drug develop discuss commonli use cancer endpoint follow discuss pertin issu canc r clinic trial design use endpoint see guidanc referenc footnot 3 regard nonsmal cell lung cancer high risk earli stage breast cancer detail discuss diseas endpoint discuss section includ overal surviv endpoint base tumor assess eg df event free surviv ef orr cr time progress ttp pf endpoint involv symptom assess blood bodi fluid base biomark emerg endpoint tabl 1 2 provid comparison endpoint cancer drug approv mani issu relat proper analysi efficaci endpoint address ich guidanc industri e9 statist principl clinic trial recommend regard use placebo blind random control clinic trial describ draft guidanc industri hematolog malign oncolog diseas consider use placebo bli nding random clinic trial drug product develop 13 cancer patient caregiv experi provid uniqu insight contribut import patient prefer inform identifi relev clinic trial endpoint ultim inform medic product develop program best meet patient need recommend stakehold collect submit patient experi data14 relev inform patient caregiv medic product develop regulatori decis make describ draft guidanc industri fda staff stakehold patient focus drug develop collect ing comprehens repres input 15 13 final guidanc repres fda current think topic address 14 21st centuri cure act httpswwwcongressgov114plawspubl255plaw 114publ255pdf 15 final guidanc repres fda current think topic address contain nonbind recommend 5 tabl 1 comparison import cancer approv endpoint note tabl sever oncolog endpoint serv differ purpos ie clinic endpoint repres clinic benefit tradit approv surrog endpoint support tradit approv surrog endpoint support acceler approv base specif context use determin base specif diseas highli depend upon factor effect size effect durat depth respons eg number cr avail therapi diseas set locat diseas clinic consequ delay prevent diseas progress delay administr toxic therapi risk benefit relationship see text detail see section v regard recommend obtain fda feedback endpoint protocol design endpoint type endpoint studi design recommend clinic endpoint surrog endpoint ta surrog endpoint aa random singl arm independ blind review overal surviv x x symptom endpoint patient report outcom x x diseas free surviv event free surviv x x x x x object respons rate x x x x x x complet respons x x x x x x progress free surviv time progress x x x x x ta tradit approv aa acceler approv alway recommend contain nonbind recommend 6 tabl 2 advantag disadvantag import cancer approv endpoint endpoint advantag disadvantag overal surviv easili precis measur gener base object quantit assess may affect switch control treatment subsequ therapi need longer followup includ noncanc death symptom endpoint patient report outcom gener assess earlier smaller sampl size compar surviv studi blind import assess endpoint potenti subject assess bia particularli open label studi lack valid instrument mani diseas area definit vari among studi balanc time assess among treatment arm critic diseas free surviv event free surviv gener assess earlier smaller sampl size compar surviv studi gener base object quantit assess potenti subject assess bia particularli open label studi definit vari among studi balanc time assess among treatment arm critic includ noncanc death object respons rate gener assess earlier smaller sampl size compar surviv studi effect tumor attribut drug natur histori gener base object quantit assess definit vari among studi frequent radiolog assess may alway correl surviv complet respons gener assess earlier smaller sampl size compar surviv studi effect tumor attribut drug natur histori gener base object quantit assess definit vari among studi frequent radiolog assess may alway correl surviv progress free surviv time progress gener assess earlier smaller sampl size compar surviv studi measur stabl diseas includ gener base object quantit assess potenti subject assess bia particularli openlabel studi es definit vari among studi frequent radiolog assess balanc time assess among treatment arm critic may alway correl surviv contain nonbind recommend 7 overal surviv overal surviv defin time random death caus measur intent totreat popul surviv consid reliabl cancer endpoint studi conduct adequ assess survi val usual prefer endpoint endpoint precis easi measur document date death bia factor endpoint measur surviv improv analyz risk benefit analysi assess clinic benefit overal surviv evalu random control studi data deriv extern control trial seldom reliabl time toevent endpoint includ overal surviv appar differ outcom extern control current treatment group aris differ drug treatment includ patient select improv imag techniqu improv support care random studi minim effect known unknown differ provid direct outcom comparison demonstr statist signific improv overal surviv consid clinic signific toxic profil accept often support new drug approva l difficulti perform analyz surviv studi includ long follow period larg trial subsequ cancer therapi potenti confound surviv analysi b endpoint base tumor assess section discuss sever endpoint base tumor assess mani cancer type radiograph umor assess direct ly measur compon diseas tumor measur commonli trigger treatment decis clinic prac tice therefor tumor measur base endpoint consid clinic relev biomark tumor measurebas endpoint may support either tradit clinic endpoint repres clinic benefit surrog endpoint tradit approv acceler approv includ df ef orr cr ttp pf tumor assess endpoint select includ two judgment first determin whether endpoint may support either acceler approv tradit approv ascertain second endpoint evalu potenti bia uncertainti drug applic use studi reli tumor assess endpoint sole evid efficaci may need confirmatori evid second trial accuraci measur tumor differ among tumor set tumor measur use orr determin imprecis locat lack demarc margin eg pleural periton mesothelioma pancreat cancer brain tumor primari studi endpoint base tumor measur eg pf orr tumor assess gener verifi central review blind studi treatment see appendix ascertain lack assess bia addit detail regard data collect list guidanc industri clinic trial endpoint approv non small cell contain nonbind recommend 8 lung cancer drug biolog appendix a16 altern random sampl base blind central review audit approach could use detail audit plan prespecifi includ strategi detect potenti assess bia bia exclud base upon audit blind central review radiograph imag necessari 17 sponsor seek fda input prior conduct audit base central review central independ verif tumor assess endpoint especi pf df may necessari random trial blind unless advers event profil would substanti unblind trial practic effect size robust larg random trial sensit analysi support lack investig bia 1 diseas free surviv event free surviv gener df defin time random diseas recurr death caus frequent use endpoint adjuv set defi nitiv surgeri radiotherapi df also import endpoint larg percentag patient achiev cr chemotherapi although overal surviv convent endpoint adjuv set df import endpoint situat surviv may prolong make overal surviv endpoint impract endpoint similar df differenti random take place definit surgeri radiotherapi adjuv set ef purpos guidanc ef defin time random follow event progress diseas preclud surgeri local distant recurr death due caus df primari basi approv adjuv breast cancer hormon therapi adjuv colon cancer adjuv cytotox breast cancer therapi wherea ef appropri endpoint evalu neoadjuv breast cancer therapi given prior definit surgeri compar standard cytotox therapi hormon therapi carri minim al side effect thu favor risk benefit relationship treatment effect measur df ef surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect diseas set avail therapi risk benefit relat hip decemb 2003 odac consensu df prolong repres clinic benefit magnitud benefit outweigh toxic adjuv treatment may 2004 odac recommend df consid clinic endpoint colon cancer drug surgic adjuv set 18 df use tradit approv diseas breast cancer colorect cancer gastrointestin stromal tumor melanoma renal cell carcinoma import consider evalu df ef potenti endpoint includ estim size treatment effect proven benefit standard therapi protocol 16 appendic guidanc industri clinic trial endpoint approv non smal l cell lung cancer drug biolog regard tumor measur data collect pf analysi also appli broadli oncolog endpoint use conjunct guidanc need 17 discuss juli 24 2012 odac meet transcript avail httpswaybackarch itorg799320170403224012httpswwwfdagovadvisorycommitteescommitteesmeetingmaterialsdrugsoncolo gicdrugsadvisorycommitteedefaulthtm 18 transcript avail httpswaybackarch itorg799320170403224012httpswwwfdagovadvi sorycommitteescommitteesmeetingmaterialsdrugsoncolo gicdrugsadvisorycommitteedefaulthtm contain nonbind recommend 9 care delin definit df ef schedul followup assess visit unschedul assess occur mani reason differ studi arm frequenc time reason unschedul assess introduc bia bia minim blind patient investig tr eatment assign appropri applic definit df ef studi complic particularli death note without prior tumor progress document event score either diseas recurr censor event although method statist analysi death limit consid death caus recurr minim bia df ef overestim use definit especi patient die long period without observ bia introduc frequenc long term follow visit dissimilar studi arm dropout random toxic analys count cancer relat death df ef event censor noncanc death method introduc bia attribut caus death furthermor method censor observ patient whether death last visit assum patient censor bservat risk recurr patient noncensor observ yet experienc event 2 object respons rate orr defin proport patient tumor size reduct predefin amount minimum time period respons durat usual measur time initi respons document tumor progress gener fda defin orr sum partial respons plu cr defin manner orr direc measur drug antitumor activ evalu singlearm studi stabl diseas compon orr stabl diseas reflect natur histori diseas wherea tumor reduct direct therapeut effect also stabl diseas accur assess ttp pf analysi see section iiib4 avail standard criteria use ascertain respons varieti respons criteria consid appropri eg revis recist guidelin version 11 19 respons criteria predefin protocol start studi signific orr assess magnitud durat percentag cr treatment effect measur orr surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect number cr durabl respons diseas set locat tumor avail therapi riskbenefit relationship 3 complet respons cr defin detect evid tumor cr gener measur imag studi eg ct can histopatholog assess eg bone marrow biopsi breast cancer resect specimen treatment effect measur cr surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud 19 eisenhau ea p therass j bogaert lh schwartz sargent r ford et al 2009 new respons evalu criteria solid tumour revis recist guidelin version 11 eur j cancer 452228 247 contain nonbind recommend 10 effect effect durat diseas set locat diseas avail therapi risk benefit relationship hematolog malign acut leukemia cr use clinic endpoint tradit approv earli high risk breast cancer patholog cr pcr use surrog endpoint acceler approv 4 time progress progress free surviv ttp pf serv primari endpoint drug approv ttp defin time random object tumor progress ttp includ death pf defin time random object tumor progress death whichev occur first precis definit tumor progress import care detail protocol compar ttp pf prefer regulatori endpoint pf includ death thu better correl overal surviv ttp analysi death event censor either time death earlier visit repres inform censor nonrandom pattern loss studi pf assum death event randomli relat tumor progress pf reflect tumor growth assess determin surviv benefit determin confound subsequ therapi given sampl size magnitud effect pf larger effect overal surviv data usual insuffici allow robust evalu correl effect overal surviv pf cancer trial often small proven surviv benefit existi ng drug gener mo dest treatment effect measur pf surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect diseas set locat metastat site avail therapi risk benefit relationship clinic consequ delay prevent progress key diseas site eg delay new lesion brain spine delay administr toxic therapi import care defin tumor progress criteria protocol standard regulatori criteria defin progress applic use varieti differ criteria includ recist criteria broad outlin present publish pf criteria supplement addit detail protocol statist analysi plan sap progress data collect multipl sourc es includ physic exam unschedul visit radiolog scan variou type differ time data collect assess visit limit specifi short time interv around schedul visit difficulti aris determin event date censor date data collect prolong time period recommend assign progress date earliest time progress observ without prior miss assess censor date last radiolog assess determin lack progress guidanc ndustri clinic trial endpoint approv nonsmal cell lung cancer drug biolog appendic c provid set tabl pote ntial analys pf use primari sensit analys plan pf data collect analysi discuss fda endof phase 2 meet contain nonbind recommend 11 5 time treatment failur time treatment failur ttf defin composit endpoint measur time random discontinu treatment reason includ diseas progress treatment toxic death ttf gener recommend regulatori endpoint new molecular entiti drug appr oval c endpoint involv symptom assess symptomat improv consid clinic benefit fda drug approv use patient symptom assess andor physic sign repres symptomat improv eg weight gain decreas effus import efficaci endpoint improv sign symptom clinic outcom assess coa use efficaci endpoint support cancer drug approv symptom assess due cancer rather drug toxic extent possibl 1 specif symptom endpoint symptom improvementpalli direct measur clinic benefit rather surrog endpoint decreas sever cancer symptom use support tradit approv anti cancer agent anti tumor activ also demonstr use symptom palliat endpoint requir popul symptomat baselin problemat mani cancer trial patient often asymptomat baselin endpoint also subject open label respons bia magnitud well describ time progress cancer symptom endpoint similar ttp also direct measur clinic benefit rather potenti surrog endpoint discuss earlier problem measur progress eg miss assess also exist evalu time symptomat progress cancer trial blind symptom assess also subject respons bia delay tumor progress onset cancer symptom occur often altern treatment initi achiev symptom endpoint confound analysi addit tumor symptom difficult differenti drug toxic composit symptom endpoint symptom scale compon similar clinic import analysi contribut compon submit primari analysi overal composit endpoint exampl composit symptom scale includ sever import symptom myelofibrosi myelofibrosi symptom assess fo rm 20 exampl composit endpoint clinic event exist patient cancer metastas skeleton drug approv base delay time skelet relat event defin patholog fractur radiat therapi bone surgeri bone spinal cord compress 20 deisseroth e kamiska j grillo w chen h sabe r hl lu et al 2012 us food drug administr approv ruxolitinib treatment patient intermedi high risk myelofibrosi c lin cancer re 1812 3212 7 contain nonbind recommend 12 select appropri popul critic document symptom benefit patient symptomat studi baselin evalu categor symptom respons analysi asymptomat patient baselin time tofirstsymptom analysi use although approach limit intermitt miss data discontinu studi drug prior symptomat progress 2 problem encount symptom data miss data infrequ assess complic evalu symptom data particularli time deterior analys procedur put place maxim complet rate trial conduct statist analysi plan outlin miss data handl data collect support multipl symptom endpoint address prospect regard multipl hypothes test necessari statist adjust specifi sap addit inform use patientreport outcom found guidanc industri patient report outcom measur use medic product develop support label claim blood bodi fluid base biomark gener b iomark assay blood bodi fluid serv primari endpoint cancer drug approv although paraprotein level measur blood urin use part myeloma respons criteria durabl major molecular respons surrog endpoint use tradit approv therapi chronic myelogen leukemia fda accept bloodbas marker element composit endpoint occurr certain clinic event signific decreas perform statu bowel obstruct conjunct mark increas ca125 consid progress ovarian cancer patient addit bloodbas biomark use identifi prognost factor select patient stratif factor consid studi design e emerg endpoint addit endpoint discuss section fda recogn advanc scienc facilit develop oncolog product may also result identif addit endpoint may use support approv oncolog product exampl minim residu diseas 21 use surrog endpoint acceler approv therapi acut lymphoblast leukemia meta tasisfre surviv use clinic endpoint tradit approv therapi non metastat castrat resist prostat cancer sponsor plan use emerg endpoint clinic develop program recommend discuss use applic fda divis offic prior initi trial see section v 21 see draft guidanc industri hematolog malign regulatori consider use minim residu diseas develop drug biolog product treatment inform assist sponsor planni ng use minim residu diseas support market approv drug biolog product treatment specif hematolog malign final guidanc repres fda current think topic address contain nonbind recommend 13 iv clinic trial design analysi consider per 21 cfr 314126 fda approv drug base substanti evid efficaci adequ well control investig describ regul studi must allow valid comparison control must provid quantit assess drug effect 22 reliabl method demonstr efficaci show statist signific improv clinic meaning endpoint random control trial ie superior follow section discuss approach may indic random control trial demonstr superior feasibl ethic sponsor plan use one approach recommend discuss use applic fda divis offic prior initi trial see section v ingl arm studi set avail therapi major tumor regress presum attribut test drug fda sometim accept orr respons durat observ singl arm studi substanti evid support acceler approv respons rate use set acut leukemia tradit approv cr associ decreas tran sfusion requir decreas infect increas surviv singl arm trial adequ character time event endpoint overal surviv df ef ttp pf variabl natur histori mani ms cancer random studi necessari evalu timetoev endpoint b random studi design demonstr noninferior noninferior ni trial demonstr new drug effect show new drug l ess effect standard regimen activ control prespecifi amount noninferior margin 23 noninferior margin clinic accept loss larger effect activ control drug standard regimen well character clinic benefit surviv benefit new drug inferior activ control noninferior margin presum ineffect ni trial reli extern ly control histor data establish activ control treatment effect size cancer trial effect frequent adequ character ni trial also reli constanc assumpt assumpt includ activ control effect remain constant extern control studi current studi assum constanc patient popul characterist support care measur evalu techniqu current trial extern control data f rom activ control effect deriv estim size activ control treatment effect base compr hensiv meta analysi extern control studi studi reliabl reproduc activ control effect compar placebo arm 22 see 21 cfr 314126b2 7 23 see guidanc industri non inferior clinic trial establish effect see also ich guidanc industri e10 choic control group relat issu contain nonbind recommend 14 difficulti conduct ni trial includ estim activ control effect determin amount effect ni margin retain ni trial usual involv larg sampl size compar superiorit trial involv replic clinic trial result furthermor subsequ therapi crossov activecontrol arm confound ni analysi ni trial endpoint overal surviv orr problemat c trial design radiotherapi protect chemotherapi protect radiotherapi protect chemotherapi protect drug design amelior toxic therapi trial usual two object first assess amelior cancer treatment toxic second object determin whether anticanc activ compromis protect second object usual examin earlier endpoint exampl orr pf rather overal surviv clinic trial design consider methodolog assess measur analyz endpoint detail protocol sap visit radiolog assess applic symmetr two studi arm prevent systemat bia fda applic agre prospect follow item applic final item initi studi extent possibl studi design definit progress sap methodolog handl miss data censor method data record case report form crf oper procedur independ endpoint review committe irc applic see appendix e c linic trial anali issu miss data complic endpoint analysi endpoint base tumor assess protocol defin adequ assess visit patient ie visit schedul tumor assess done analysi plan outlin comparison adequaci follow treatment arm methodolog analyz incomplet andor miss follow visit censor method specifi protocol analysi plan specifi pri mari analysi one sensit analys evalu robust result although analys miss data problemat result strengthen similar result primari sensit analys applic evalu includ number death patient lost follow prolong time period exampl imbal death could bia pf measur overestim pf treatment arm less follow contain nonbind recommend 15 v conclus although gener principl outlin guidanc help applic select endpoint market applic recommend applic meet fda submit protocol intend support nda bla market applic fda ensur meet includ multidisciplinari fda team oncologist statistician clinic pharmacologist extern expert consult need applic submit protocol meet request special protocol assess ment provid confirm accept endpoint protocol design support drug market applic 24 ultim cours market approv depend design clinic trial fda review result data studi drug market applic 24 see guidanc industri special protocol assess contain nonbind recommend 16 appendix independ review tumor en dpoint clinic trial result support drug approv verifi applic food drug administr fda object respons r ate orr determin singl arm studi evalu review limit number imag drug approv base measur progress free surviv pf care plan minim bia enabl applic fda verifi result independ endpoint review committe irc minim bia radiograph interpret radiolog find independ adjud assess clearli written plan charter outlin irc fu nction process independ review charter place initi studi plan describ assur committe independ procedur collect storag transport result charter also includ resolut differ interpret incorpor clinic data final interpret data audit procedur use irc discuss guidanc industri develop medic imagi ng drug biolog product part 3 design analysi interpret clinic studi